Relation between the Duration of Remission and Hyperglycemia during Induction Chemotherapy for Acute Lymphocytic Leukemia with a Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone/Methotrexate-Cytarabine Regimen

Cancer

Volumn 100, Issue 6, 2004, Pages 1179-1185

  Weiser, Mary Ann ^a   Cabanillas, Maria E ^a   Konopleva, Marina ^a   Thomas, Deborah A ^a   Pierce, Sherry A ^a   Escalante, Carmen P ^a   Kantarjian, Hagop M ^a   O'Brien, Susan M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute lymphocytic leukemia (ALL); Complete remission duration (CRD); Complications; Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper CVAD chemotherapy); Hyperglycemia; Mortality; Steroids

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; GLUCOSE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INSULIN; METHOTREXATE; METHYLPREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CELL METABOLISM; CELL PROLIFERATION; COMPLETE REMISSION DURATION; DISEASE DURATION; DOSE TIME EFFECT RELATION; FEMALE; GLUCOSE METABOLISM; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; INFECTION COMPLICATION; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOSA INFLAMMATION; MYCOSIS; NEUTROPENIA; OUTCOMES RESEARCH; PERIPHERAL NEUROPATHY; PNEUMONIA; PREDICTION; PREVALENCE; PRIORITY JOURNAL; REMISSION; RISK FACTOR; SEPSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FEMALE; HUMANS; HYPERGLYCEMIA; INFECTION; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; METHOTREXATE; REMISSION INDUCTION; TIME FACTORS; VINCRISTINE;

EID: 1542314287     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20071     Document Type: Article

References (13)

1. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18:547-561.
2. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients [comment]. N Engl J Med. 2001;345:1359-1367.
3. Umpierrez GE, Isaacs SD, Bazargan N, et al. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes [comment]. J Clin Endocrinol Metab. 2002;87:978-982.
4. Boros LG, Lee WN, Go VL. A metabolic hypothesis of cell growth and death in pancreatic cancer. Pancreas. 2002;24:26-33.
5. Boren J, Cascante M, Marin S, et al. Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J Biol Chem. 2001;276:37747-37753.
6. Meyerhardt JA, Catalano PJ, Haller DG, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 2003;21:433-440.
7. Chan JC, Cockram CS, Critchley JA. Drug-induced disorders of glucose metabolism. Mechanisms and management. Drug Saf. 1996;15:135-157.
8. Eschwege E, Balkau B. Hyperglycaemia: link to excess mortality. Int J Clin Pract Suppl. 2001;(123):3-6.
9. Maestu I, Pastor M, Gomez-Codina J, et al. Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patients. Ann Oncol. 1997;8:547-553.
10. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999;48:937-942.
11. Bagdade JD, Root RK, Bulger RJ. Impaired leukocyte function in patients with poorly controlled diabetes. Diabetes. 1974;23:9-15.
12. Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002;20:42-51.
13. Gapstur SM, Gann PH, Colangelo LA, et al. Postload plasma glucose concentration and 27-year prostate cancer mortality (United States). Cancer Causes Control. 2001;12:763-772.